Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity T. FukasawaN. Yasui–FurukoriK. Otani Pharmacogenetics 01 November 2005 Pages: 791 - 795
Identification of CYP2D6 impaired functional alleles in Mexican Americans Huai-Rong LuoAndrea GaedigkYu-Jui Yvonne Wan Pharmacogenetics 08 November 2005 Pages: 797 - 802
Polymorphisms of IL–13 and IL–4–IL–13–SNPs in patients with penicillins allergy Jing YangHai–Ling QiaoZi–Ming Dong Pharmacogenetics 17 November 2005 Pages: 803 - 809
Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study Tuomo NieminenHannu UusitaloMika Kähönen Pharmacogenetics 17 November 2005 Pages: 811 - 819
Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects Christian Funck-BrentanoPierre-Yves BoëlleJean-Marie Poirier Pharmacogenetics 17 November 2005 Pages: 821 - 829
Effect of gemfibrozil on the pharmacokinetics of pioglitazone Li-Jing DengFeng WangHuan-De Li Pharmacokinetics and Disposition 08 November 2005 Pages: 831 - 836
O-demethylation of tramadol in the first months of life Karel AllegaertJ. N. Van den AnkerH. Devlieger Pharmacokinetics and Disposition 08 November 2005 Pages: 837 - 842
No evidence of gemcitabine accumulation during weekly administration S. M. de LangeK. van der BornG. J. Peters Pharmacokinetics and Disposition 10 November 2005 Pages: 843 - 849
How do psychiatrists choose among different antipsychotics? Johannes HamannGrit KolbeWerner Kissling Pharmacoepidemiology and Prescription 19 October 2005 Pages: 851 - 854
Psychotropic combination in schizophrenia E. AcquavivaI. GasquetB. Falissard Pharmacoepidemiology and Prescription 08 November 2005 Pages: 855 - 861